Clinical Trials For frontotemporal dementia To Start By 2013

.

Clinical Trials For frontotemporal dementia To Start By 2013

A neurodegenerative disease, frontotemporal dementia starts with silence and damages personality traits and then affects the brain. It gets very late for doctors to address the problem and till the time they get to know about, a person suffering from it, is left with very less time.

The disease was first discovered some 100 years back, but then also researchers have not been able to find probable reasons as well as treatment of the problem. It has also been found those maximum survival years of person after diagnosis of disease is not more than eight years.

However, researchers at the University of California have identified drugs that can treat the rare neurodegenerative problem. It is said that the study researchers are going to initiate clinical trials for the same by 2013.

Dr. Bruce L. Miller, who is a Professor of neurology and psychiatry in University of California, said that it is high time that researchers should know that there are different subtypes of dementia. "I think at least some subtypes of frontotemporal dementia will be the first neurodegenerative diseases we find a cure for", said Miller.

Miller further said that there are chances that the development helps understanding Alzheimer's disease in a better way.


Latest News

Feds Expected to Trim Bond Purchases, Could Also Offer Hazy Clues on Interest Ra
After First Six Months of Sales Toyota Remains at Top
McDonald's Franchisee ruling Gives Rise to Business-Labour Arguments
Breakage in Main Pipe Causes Havoc in UCLA
Southwest Airlines to Be Charged a Fine of $12 million Over Issues Related to Re
Zillow to Purchase Trulia; A Merger That Will Create a Real Estate Giant Listing
More than One Third of Americans Debt Offenders
Video Shows Baby Turtles Heading to Sea
Bear Stearns, Alan 'Ace' Greenberg, dies at 86
Former U.S. official Says President Obama Could Restrain Corporate 'Inversions'
As U.S. Stocks Ascend, NYC Pension Funds Report 17.4%  Returns on Investments
Food Scandal in China, Parent Company to Investigate Matters